|Mr. Bruce C. Cozadd
|Co-Founder, Chairman & CEO
|Ms. Reneé D. Galá
|President & COO
|Mr. Daniel N. Swisher Jr.
|Dr. Robert Iannone M.D.
|Executive VP and Global Head of Research & Development
|Ms. Patricia Carr
|Senior VP, CFO, & Chief Accounting Officer
|Ms. Andrea N. Flynn Ph.D.
|VP & Head of Investor Relations
|Ms. Neena M. Patil J.D.
|Executive VP & Chief Legal Officer
|Dr. George Christopher Eliades Ph.D.
|Senior VP of Corporate Development & Chief Transformation Officer
|Ms. Heidi Manna
|Senior VP & Chief People Officer
|Dr. Jed Black M.D.
|Senior Vice President of Sleep & CNS Medicine
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. It offers medicines products, including therapies for sleep disorders and epilepsy, and cancer treatment. The company's lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy and to treat idiopathic hypersomnia; Xyrem, for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. Its lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; and Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase. It has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Jazz Pharmaceuticals plcs ISS Governance QualityScore, Stand 1. März 2024, lautet 3. Die grundlegenden Scores sind Audit: 6, Vorstand: 3, Shareholderrechte: 3, Kompensation: 4.